A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: A Hellenic Cooperative Oncology Group study

BMC Medicine

Volumn 8, Issue , 2010, Pages

  Bafaloukos, Dimitrios ^a   Linardou, Helena ^a   Aravantinos, Gerasimos ^b   Papadimitriou, Christos ^c   Bamias, Aristotelis ^c   Fountzilas, George ^d   Kalofonos, Haralabos P ^e   Kosmidis, Paris ^f   Timotheadou, Eleni ^d   Makatsoris, Thomas ^e   Samantas, Epaminondas ^b   Briasoulis, Evangelos ^g   Christodoulou, Christos ^a   Papakostas, Pavlos ^h   Pectasides, Dimitrios ⁱ   Dimopoulos, Athanasios M ^c  

^a METROPOLITAN HOSPITAL   (Greece)

^b AGII ANARGIRI CANCER HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^e UNIVERSITY OF PATRAS   (Greece)

^f HYGEIA HOSPITAL   (Greece)

^g UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^h Ippokration Hospital Thessaloniki   (Greece)

ⁱ NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DOCETAXEL; DOXORUBICIN; PACLITAXEL; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MACROGOL DERIVATIVE;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HAND FOOT SYNDROME; HISTOLOGY; HUMAN; HYPERSENSITIVITY; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; VOMITING; KAPLAN MEIER METHOD; MIDDLE AGED; OVARY TUMOR; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DOXORUBICIN; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; POLYETHYLENE GLYCOLS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME;

EID: 76949103190     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-8-3     Document Type: Article

References (29)

1. American Cancer Society Cancer Facts and Figures 2007. 2007, Georgia: American Cancer Society, American Cancer Society.
2. du Bois A, Lück HJ, Meier W, Adams HP, Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003, 95:1320-1330.
3. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R, . Gynecologic Oncology Group Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003, 21:3194-3200. 10.1200/JCO.2003.02.153, 12860964, Gynecologic Oncology Group.
4. Vasey PA, Herrstedt J, Jelic S, . ESMO Guidelines Task Force ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of epithelial ovarian carcinoma. Ann Oncol 2005, 16(suppl 1):i13-15. 10.1093/annonc/mdi823, 15888736, ESMO Guidelines Task Force.
5. Eisenhauer EA, Vermorken JC, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 1997, 8:963-968. 10.1023/A:1008240421028, 9402168.
6. Markman M, Markman J, Webster K, Zanotti K, Kulp B, Peterson G, Belinson J. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 2004, 22:3120-3125. 10.1200/JCO.2004.05.195, 15284263.
7. Colombo N, Gore M. Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy. Crit Rev Oncol Hematol 2007, 64:129-138. 10.1016/j.critrevonc.2007.04.004, 17566758.
8. Dizon DS, Dupont J, Anderson S, Sabbatini P, Hummer A, Aghajanian C, Spriggs D. Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Centre experience. Gynecol Oncol 2003, 91:584-590. 10.1016/j.ygyno.2003.08.017, 14675681.
9. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003, 361:2099-2106. 10.1016/S0140-6736(03)13718-X, 12826431.
10. Gonzalez-Martin AJ, Calvo E, Bover I, Rubio MJ, Arcusa A, Casado A, Ojeda B, Balañá C, Martínez E, Herrero A, et al. Randomised phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO study. Ann Oncol 2005, 16:749-755. 10.1093/annonc/mdi147, 15817604.
11. Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, Wagner U, Stähle A, Stuart G, Kimmig R, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006, 24:4699-4707. 10.1200/JCO.2006.06.0913, 16966687.
12. O'Byrne KJ, Bliss P, Graham JD, Gerber J, Vasey PA, Khanna S, Gore M. A phase III study of Doxil/Caelyx versus paclitaxel in platinum-treated, taxane-naïve relapsed ovarian cancer (abstract 808). Proc Am Soc Clin Oncol 2002, 21:203a.
13. Doxil Study 30-49 Investigators Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004, 95:1-8. 10.1016/j.ygyno.2004.07.011, 15385103, Doxil Study 30-49 Investigators.
14. du Bois A, Burges A, Meier W, Pfisterer J, Schmalfeldt B, Richter B, Jackisch C, Staehle A, Kimmig R, Elser G, . Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom Pegylated liposomal doxorubicin and carboplatin in advanced gynaecologic tumors: a prospective phase I/II study of the Arbeitsgemeinschaft Gynaecologische Onkologie Studengruppe Ovarialkarzinom (AGO-OVAR). Ann Oncol 2006, 17:93-96. 10.1093/annonc/mdj032, 16282248, Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom.
15. du Bois A, Pfisterer J, Burchardi N, Loibl S, Huober J, Wimberger P, Burges A, Stähle A, Jackisch C, Kölbl H, . Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom; Kommission Uterus Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynaecologische Onkologie Studengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut). Gynecol Oncol 2007, 107:518-525. 10.1016/j.ygyno.2007.08.008, 17910981, Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom; Kommission Uterus.
16. Ferrero JM, Weber B, Geay JF, Lepille D, Orfeuvre H, Combe M, Mayer F, Leduc B, Bourgeois H, Paraiso D, Pujade-Lauraine E. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol 2007, 18:263-268. 10.1093/annonc/mdl376, 17108151.
17. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989, 7:1748-1756.
18. Rustin GJ, Nelstrop AE, Bentzen SM, Piccart MJ, Bertelsen K. Use of tumour markers in monitoring the course of ovarian cancer. Ann Oncol 1999, 10:21-27. 10.1023/A:1008351216605, 10219449.
19. Moher D. CONSORT: An evolving tool to help improve the quality of reports of randomized controlled trials. JAMA 1998, 279:1489-1491. 10.1001/jama.279.18.1489, 9600488.
20. Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 2002, 7:20-28. 10.1634/theoncologist.7-suppl_5-20, 12324630.
21. Pignata S, de Placido S, Biamonte R, Scambia G, Di Vagno G, Colucci G, Febbraro A, Marinaccio M, Lombardi AV, Manzione L, et al. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. BMC Cancer 2006, 6:5-11. 1361775, 16398939, 10.1186/1471-2407-6-5.
22. Tomblyn MR, Rizzo JD. Are There circumstances in which phase 2 study results should be practice-changing?. Hematology Am Soc Hematol Educ Program 2007, 2007:489-492.
23. Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, Libson E, Muggia FM, Gabizon A. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995, 13:1777-1785.
24. Sehouli J, Camara O, Schmidt M, Mahner S, Seipelt G, Otremba B, Schmalfeldt B, Tesch H, Lorenz-Schlüter C, Oskay-Ozcelik G, . North-Eastern German Society of Gynecological Oncology Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study. Cancer Chemother Pharmacol 2009, 64:585-591. 10.1007/s00280-008-0909-1, 19156414, North-Eastern German Society of Gynecological Oncology.
25. Pignata S, Scambia G, Savarese A, Breda E, Scollo P, De Vivo R, Rossi E, Gebbia V, Natale D, Del Gaizo F, , et al. MITO Investigators Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomised trial. BMC Cancer 2006, 6:202-208. 1553473, 16882344, 10.1186/1471-2407-6-202, MITO Investigators.
26. Rose PG. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. Oncologist 2005, 10:205-214. 10.1634/theoncologist.10-3-205, 15793224.
27. Alberts DS, Liu PY, Wilczynski SP, Clouser MC, Lopez AM, Michelin DP, Lanzotti VJ, Markman M, . Southwest Oncology Group Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). Gynecol Oncol 2008, 108:90-94. 2276605, 17949799, 10.1016/j.ygyno.2007.08.075, Southwest Oncology Group.
28. Pujade-Lauraine E, Mahner S, Kaern J, Gebski V, Heywood M, Vasey P, Reinthaller A, Vergote I, Pignata S, Ferrero A. A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG). J Clin Oncol 2009, 27:18s. (suppl; abstr LBA5509).
29. Pignata S, Scambia G, Savarese A, Sorio R, Breda E, Ferrandina G, Gebbia V, Musso P, Gallo C, Perrone F. Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): Activity and safety results of the MITO-2 randomized multicenter trial. J Clin Oncol 2009, 27:18s. (suppl; abstr LBA5508).